KHK6640 / OncoTherapy - LARVOL DELTA

Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer's Disease. (PubMed, J Prev Alzheimers Dis) - "KHK6640 was well-tolerated across all doses, without any amyloid-related imaging abnormalities for edema, and amyloid-related imaging abnormalities for hemorrhage was as population background. The demonstrated dose-response of specific target biomarkers provides dosing guidance on dose and administration method selection for further clinical development."

Clinical • Journal • P1/2 data • Alzheimer's Disease • CNS Disorders • Hematological Disorders

PHARMACOLOGICAL PROFILES OF ANTI- AMYLOID Β AGGREGATE-SPECIFIC ANTIBODY KHK6640 BOTH IN VITRO AND IN VIVO INCLUDING A NOVEL CLINICALLY RELEVANT RODENT MODEL OF ALZHEIMER’S DISEASE. (CTAD 2019) - "There is controversy about which form of Aβ is responsible for AD pathogenesis; many of the synthetic, cell culture, and Tg animal-derived AD forms seem quite different from what has been observed in humans. Recently, however, research progress in the AD eld support that AD pathogenesis is associated with soluble toxic Aβ oligomers and not with insoluble Aβ species. KHK6640 exhibited a binding pro le selectively for Aβ aggregates (i.e."

Pharmacological profiles of anti-amyloid β aggregate-specific antibody KHK6640 both in vitro and in vivo including a novel clinically relevant rodent model of Alzheimer’s disease (CTAD 2019) - No abstract available.